Active Ingredient History
CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and induced by lymphocyte activation (ILA). It is of interest to immunologists as a co-stimulatory immune checkpoint molecule, and as a potential target in cancer immunotherapy. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Biomarkers (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 3)
Colorectal Neoplasms (Phase 1)
Lymphoma (Phase 3)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Melanoma (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Oropharyngeal Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue